医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

European Patent Office Upholds Validity of Mitsubishi Chemical’s Patent on Biomass-based High-quality Polyester

2016年06月20日 PM08:31
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsubishi Chemical Corporation (MCC; Head office: Chiyoda-ku, Tokyo; President: Hiroaki Ishizuka) today announced that the European Patent Office (EPO) on May 17 issued a notice maintaining the patent owned by MCC (EP1882712B; “the patent”), which is a basic patent for a biomass-based polyester. Several corporations and others had filed notices of opposition to the validity of the patent. However, the EPO largely sided with MCC’s position as to the patent’s validity following the oral proceedings on April 15 of this year.

It is a substance patent for a biomass-based high-quality polyester, and is vastly applicable for business activities such as manufacturing and sales. The corresponding patents have also been granted in Japan, the U.S., and China. The EPO’s decision supports the patent’s validity, and MCC will move proactively to defend the patent against future similar objections.

“MCC owns many other patents relating to biomass-based products. It continually expands its own businesses by utilizing those patents and provides licenses to other companies, in order to promote the spread of those products and contribute to global environmental sustainability,” stated Johei Takimoto, Chief Operation Officer, the Polymer Division.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005620/en/

CONTACT

For further information, please contact:
Mitsubishi Chemical
Holdings Corporation
Satoshi Kofukata, [+81] (0)3-6748-7140
Public
Relations and Investor Relations Office

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
  • TL PLASTIC SURGERY in South Korea, the Best Choice for Your Satisfying Breast Augmentation Surgery
  • Ascendia Pharmaceuticals宣布其治疗急性冠脉综合征的ASD-002项目获颁一项新专利
  • 年次世界患者安全・科学・技術サミットで初めて米国外向けにHDライブストリーミングを実施へ
  • Accelsiors CRO Expands Global Footprint